Patient-Derived Gastric Cancer Assembloids Reveal Stromal Impact on Drug Response

Study Background and Research Question

Gastric cancer remains a major clinical challenge, ranking as the fifth most frequently diagnosed carcinoma and the second leading cause of cancer-related deaths globally. Despite advances in surgery, chemotherapy, targeted therapy, and immunotherapy, the five-year survival rate for advanced or metastatic gastric cancer remains below 10%. This poor prognosis is largely attributed to the pronounced heterogeneity of gastric tumors and the complexity of their microenvironments, which drive variable treatment responses and frequent therapeutic resistance. Conventional three-dimensional (3D) tumor organoid models have advanced cancer research by allowing ex vivo culture of patient-derived tumor cells, but they often fail to recapitulate the cellular and molecular diversity of the tumor stroma. Consequently, there remains a need for preclinical models that more faithfully mimic the tumor niche and enable robust investigation of individualized tumor biology and therapeutic responses.

Key Innovation from the Reference Study

The reference study introduces a next-generation assembloid platform that integrates patient-derived gastric cancer organoids with matched stromal cell subpopulations, including mesenchymal stem cells, fibroblasts, and endothelial cells. By leveraging autologous stromal cells isolated from the same tumor tissue as the epithelial component, the model achieves a level of microenvironmental fidelity not attainable with traditional organoid cultures. This innovation allows for the assessment of stromal influence on tumor cell gene expression, biomarker profiles, and response to pharmacological agents in a setting that closely mirrors in vivo tumor complexity.

Methods and Experimental Design Insights

The workflow begins with the enzymatic dissociation of fresh gastric tumor tissue, followed by expansion of epithelial and stromal subpopulations in tailored growth media. Organoids were cultured in conditions optimized for tumor epithelial cells, while stromal fractions—including fibroblasts, mesenchymal stem cells, and endothelial cells—were expanded using lineage-specific protocols. The critical step involved reconstituting these cell types in an optimized assembloid medium supporting the survival and growth of all components. This co-culture system was validated by immunofluorescence staining for epithelial and stromal markers, confirming preservation of lineage identity and tissue architecture. RNA sequencing was employed to analyze transcriptomic changes and differential gene expression driven by tumor-stroma interactions. Pharmacological responsiveness was assessed through cell viability assays following exposure to diverse therapeutic agents, providing a quantitative readout of drug efficacy in both monoculture and assembloid contexts.

Protocol Parameters

• Tumor tissue dissociation: Enzymatic digestion to generate single-cell suspensions, followed by separation into epithelial and stromal fractions.
• Expansion media: Organoids grown in tumor-specific medium; stromal subpopulations (fibroblasts, mesenchymal stem cells, endothelial cells) expanded in lineage-appropriate media.
• Assembloid formation: Co-culture of tumor organoids and stromal cells in an optimized medium, supporting all subtypes in a 3D matrix.
• Biomarker analysis: Immunofluorescence staining for epithelial (e.g., E-cadherin) and stromal (e.g., vimentin, α-SMA) markers.
• Transcriptomics: RNA sequencing of assembloid and monoculture samples to assess differential gene expression.
• Drug response assays: Cell viability measurements after treatment with targeted agents and chemotherapeutics.

Core Findings and Why They Matter

Assembloids generated under this protocol demonstrated cellular heterogeneity and architectural features closely resembling those of the primary tumor, surpassing monocultures in their expression of both epithelial and stromal markers. Notably, assembloids exhibited elevated levels of inflammatory cytokines, extracellular matrix remodeling factors, and genes associated with tumor progression, reflecting enhanced paracrine and juxtacrine signaling between tumor and stroma. Functional drug screening revealed striking differences in drug responsiveness between organoid-only cultures and assembloids. While certain agents retained efficacy in both contexts, others lost potency in the presence of stromal cells, underscoring the stroma’s role in mediating intrinsic and acquired resistance mechanisms. These results highlight the importance of including stromal components in preclinical models to more accurately predict patient-specific drug responses and to identify potential resistance pathways for future therapeutic targeting.

By enabling high-resolution investigation of tumor–stroma interactions, this assembloid model offers a valuable resource for cancer biology research, particularly in the context of tyrosine kinase signaling pathway modulation and MAP kinase pathway inhibition—both of which are central to tumor progression and therapeutic resistance.

Comparison with Existing Internal Articles

The innovation described in the reference paper aligns with themes explored in several recent mechanistic and workflow-focused publications. For instance, the article "Imatinib (STI571): Selective Inhibition in Advanced Signa..." highlights Imatinib’s role as a selective inhibitor of PDGF receptor, c-Kit, and Abl kinases, which are frequently studied in co-culture systems to dissect tumor–stroma crosstalk and resistance mechanisms. The assembloid framework described in the reference study provides an ideal platform to expand such research by enabling the precise assessment of kinase inhibitor effects within a physiologically relevant context. Furthermore, the article "Redefining Translational Oncology: Mechanistic Insights a..." discusses the application of selective tyrosine kinase inhibitors in complex assembloid systems to unravel resistance mechanisms and guide personalized therapy strategies. These internal resources, when paired with the advanced assembloid model, can facilitate novel investigations into the interplay between kinase signaling, stromal modulation, and therapeutic outcomes.

Additionally, recent work on signal transduction research, such as "Imatinib (STI571): Applied Workflows in Tyrosine Kinase Research", offers actionable protocols for kinase inhibition assays that can be adapted to the assembloid context, further enhancing reproducibility and translational impact.

Limitations and Transferability

Despite its marked advantages, the assembloid system described in the reference study has several limitations. The protocol requires access to fresh patient tumor tissue and specialized cell culture expertise, potentially limiting scalability in routine settings. Additionally, while the inclusion of major stromal subtypes improves model fidelity, the tumor microenvironment comprises other cell types—such as immune cells—that are not yet fully integrated into this platform. Furthermore, drug response assays may be influenced by batch effects or inter-patient variability, calling for careful standardization and validation across diverse clinical samples. Transferability to other tumor types or broader drug classes will require further optimization of co-culture conditions and validation of marker expression profiles. Nevertheless, the assembloid model represents a significant advance in preclinical cancer modeling and holds promise for accelerating the translation of personalized therapeutic strategies.

Research Support Resources

To support signal transduction research and kinase inhibition studies in assembloid or organoid models, researchers may utilize Imatinib (STI571) (SKU B2171), a selective PDGF receptor, c-Kit, and Abl kinase inhibitor widely adopted in cancer biology research. According to the product information, Imatinib exhibits sub-micromolar potency across these kinases and is suitable for use in cell-based kinase inhibition, pathway dissection, and drug resistance assays. For protocols involving 3D cultures or assembloids, Imatinib’s solubility profile and recommended concentrations (0–10 μM at 37°C for short-term treatments) may facilitate accurate modeling of tyrosine kinase signaling pathway inhibition in a physiologically relevant context. For further technical guidelines, APExBIO provides detailed storage and handling instructions to ensure experimental reproducibility.